Adaptive Biotechnologies Corp
Suletud
17.26 3.23
Ülevaade
Aktsiahinna muutus
24h
Min
16.47
Max
17.52
Sissetulek | -6.4M -20M |
|---|---|
Müük | -807K 71M |
Aktsiakasum | -0.13 |
Kasumimarginaal | -28.24 |
Töötajad | 624 |
EBITDA | -7.9M -14M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +19.35% upside |
Järgmine tulemuste avaldamine | 4. aug 2026 |
|---|
Turukapital | 121M 2.4B |
|---|---|
Eelmine avamishind | 14.03 |
Eelmine sulgemishind | 17.26 |
Adaptive Biotechnologies Corp Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Adaptive Biotechnologies Corp Prognoos
Hinnasiht
By TipRanks
19.35% tõus
12 kuu keskmine prognoos
Keskmine 20.17 USD 19.35%
Kõrge 22 USD
Madal 18 USD
Põhineb 8 Wall Streeti analüütiku instrumendi Adaptive Biotechnologies Corp 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
